arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Curanex Pharmaceuticals Inc

CURX

$0.20 ▼ -0.01 (-2.74%) at close

10 Visible periods

17 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Bearish

auto_awesome

Analytical Summary

Curanex Pharmaceuticals Inc faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $5.7M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -31.1% ↘

FCF / Share $-0.03

Trailing P/E —

Price / Book 0.7x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

10-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-3.15M

↓ -2189.7% —

FCF / Share Free cash flow per share

$-0.03

↓ -439.0% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
EPS Growth YoY (%)	-1000.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	N/M	0.0% Caution Caution Year-over-year change in earnings per share Optimal: > 10%	100.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	-2189.7% Weak ↓ Weak Declining Year-over-year change in net income	-2005.8% Weak ↓ Weak Declining Year-over-year change in net income	-71.5% Weak Weak Year-over-year change in net income	-71.5% Weak Weak Year-over-year change in net income	—	—	—	—	—	—
FCF Growth YoY (%)	-439.0% Weak Weak Year-over-year change in free cash flow	—	-562.8% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
FCF / Net Income (x)	0.30x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.28x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	66.77x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	2.11x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	1.09x Fair → Fair Stable Free cash flow relative to reported net income Optimal: > 1x	0.65x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	1.62x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Return on Invested Capital (%)	-31.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-21.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-5.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-14.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-29.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-23.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-11.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-4.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-37.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-26.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-6.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-7.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	-28.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-39.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-360%)	-27.4% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-283%)	-1.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-106%)	-45.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-400%)	-37.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-351%)	-29.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-293%)	-12.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-186%)	-11.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-175%)	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Net Debt (USD)	$-4.00M	$-5.00M	$-5.80M	—	—	—	—	—	—	—

📊 What does each share earn? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Basic EPS, GAAP (USD)	$-0.11	$-0.12	$-0.04	$0.00	$-0.01	$0.02	$-0.04	$-0.02	—	—
Free Cash Flow per Share (USD)	$-0.03	—	$-0.36	$-0.01	$-0.01	—	$-0.05	—	—	—
Book Value per Share (USD)	$0.28	$0.40	$0.50	$0.01	$0.02	$0.02	$0.26	$0.30	—	—
Tangible Book Value per Share (USD)	$0.28	$0.40	$0.50	$0.01	$0.02	$0.02	$0.26	$0.30	—	—
Basic Weighted Avg Shares (shares)	28.34M	—	25.60M	24.00M	24.00M	—	2.40M	2.40M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Working Capital (USD)	$7.96M	$11.09M	$14.23M	$635.41K	—	$503.36K	—	—	—	—
Total Equity (USD)	$8.08M	$11.22M	$14.29M	$305.43K	$365.78K	$503.36K	$624.16K	$715.23K	$129.89K	$60.09K

📋 What is driving earnings? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Net Income, GAAP (USD)	$-3.15M	$-3.07M	$-137.58K	$-137.58K	$-137.58K	$-145.94K	$-80.20K	$-80.20K	—	—
Operating Cash Flow (USD)	$-954.56K	$-857.40K	$-9.19M	$-290.08K	$-149.95K	$-95.43K	$-129.94K	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 3 years · 10 quarters

Curanex Pharmaceuticals Inc

Analytical Summary

10-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CURX with peers